Eliglustat free base
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314252

CAS#: 491833-29-5 (free base)

Description: Eliglustat, also known as GENZ-112638, (trade name Cerdelga) is a treatment for Gaucher's disease developed by Genzyme Corp that was approved by the FDA August 2014. Commonly used as the tartrate salt, Eliglustat is believed to work by inhibition of glucosylceramide synthase.


Chemical Structure

img
Eliglustat free base
CAS# 491833-29-5 (free base)

Theoretical Analysis

MedKoo Cat#: 314252
Name: Eliglustat free base
CAS#: 491833-29-5 (free base)
Chemical Formula: C23H36N2O4
Exact Mass: 404.2675
Molecular Weight: 404.551
Elemental Analysis: C, 68.29; H, 8.97; N, 6.92; O, 15.82

Size Price Shipping out time Quantity
25mg USD 150 Same day
50mg USD 250 Same day
100mg USD 450 Same day
200mg USD 750 Same day
500mg USD 1050 Same day
1g USD 1850 Same day
2g USD 2950 Same day
5g USD 3950 Same day
10g USD 6850 2 weeks
Inquire bulk and customized quantity

Pricing updated 2021-03-01. Prices are subject to change without notice.

Eliglustat free base purity > 98%, is in stock. The same day shipping out after order is received.

Related CAS #: 928659-70-5 (tartrate)   491833-29-5 (free base)    

Synonym: GENZ112638; GENZ 112638; GENZ-112638; UNIIN0493335P3; Eliglustat tartrate (USAN); eliglustat hemitartrate; Eliglustat; trade name Cerdelga.

IUPAC/Chemical Name: N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)octanamide

InChi Key: FJZZPCZKBUKGGU-AUSIDOKSSA-N

InChi Code: InChI=1S/C23H36N2O4/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26)/t19-,23-/m1/s1

SMILES Code: CCCCCCCC(N[C@H](CN1CCCC1)[C@@H](C2=CC=C3OCCOC3=C2)O)=O

Appearance:
White to off-white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO.

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
Soluble in DMSO. 100.0

Preparing Stock Solutions

The following data is based on the product molecular weight 404.551 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Murugesan V, Chuang WL, Liu J, Lischuk A, Kacena K, Lin H, Pastores GM, Yang R, Keutzer J, Zhang K, Mistry PK. Glucosylsphingosine is a key biomarker of Gaucher disease. Am J Hematol. 2016 Nov;91(11):1082-1089. doi: 10.1002/ajh.24491. PubMed PMID: 27441734.

2: Pleat R, Cox TM, Burrow TA, Giraldo P, Goker-Alpan O, Rosenbloom BE, Croal LR, Underhill LH, Gaemers SJ, Peterschmitt MJ. Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial. Mol Genet Metab Rep. 2016 Sep 30;9:25-28. PubMed PMID: 27722092; PubMed Central PMCID: PMC5050260.

3: Belmatoug N, Di Rocco M, Fraga C, Giraldo P, Hughes D, Lukina E, Maison-Blanche P, Merkel M, Niederau C, Plӧckinger U, Richter J, Stulnig TM, Vom Dahl S, Cox TM. Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe. Eur J Intern Med. 2016 Aug 10. pii: S0953-6205(16)30217-5. doi: 10.1016/j.ejim.2016.07.011. [Epub ahead of print] Review. PubMed PMID: 27522145.

4: Cohen IJ, Baris H, Mistry PK, Sands MS. Overcoming the Next Barriers to Successful Therapy. Pediatr Endocrinol Rev. 2016 Jun;13 Suppl 1:629. PubMed PMID: 27491209.

5: Erratum: Profile of eliglustat tartrate in the management of Gaucher disease [Corrigendum]. Ther Clin Risk Manag. 2016 Jul 7;12:1083. doi: 10.2147/TCRM.S108027. PubMed PMID: 27462161; PubMed Central PMCID: PMC4939999.

6: Ibrahim J, Underhill LH, Taylor JS, Angell J, Peterschmitt MJ. Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry. Mol Genet Metab Rep. 2016 Jun 27;8:17-9. doi: 10.1016/j.ymgmr.2016.06.003. PubMed PMID: 27408819; PubMed Central PMCID: PMC4927653.

7: Smid BE, Ferraz MJ, Verhoek M, Mirzaian M, Wisse P, Overkleeft HS, Hollak CE, Aerts JM. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients. Orphanet J Rare Dis. 2016 Mar 24;11:28. doi: 10.1186/s13023-016-0413-3. PubMed PMID: 27008851; PubMed Central PMCID: PMC4806476.

8: Shayman JA. Targeting Glycosphingolipid Metabolism to Treat Kidney Disease. Nephron. 2016;134(1):37-42. doi: 10.1159/000444926. PubMed PMID: 26954668.

9: Sechi A, Dardis A, Bembi B. Profile of eliglustat tartrate in the management of Gaucher disease. Ther Clin Risk Manag. 2016 Jan 11;12:53-8. doi: 10.2147/TCRM.S73226. Review. Erratum in: Ther Clin Risk Manag. 2016;12:1083. PubMed PMID: 26811686; PubMed Central PMCID: PMC4714736.

10: Shayman JA. Developing novel chemical entities for the treatment of lysosomal storage disorders: an academic perspective. Am J Physiol Renal Physiol. 2015 Dec 15;309(12):F996-9. doi: 10.1152/ajprenal.00393.2015. Review. PubMed PMID: 26447223.

11: Yu J, Ritchie TK, Zhou Z, Ragueneau-Majlessi I. Key Findings from Preclinical and Clinical Drug Interaction Studies Presented in New Drug and Biological License Applications Approved by the Food and Drug Administration in 2014. Drug Metab Dispos. 2016 Jan;44(1):83-101. doi: 10.1124/dmd.115.066720. Review. PubMed PMID: 26424199.

12: Erratum: Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease [Corrigendum]. Drug Des Devel Ther. 2015 Sep 11;9:5213. doi: 10.2147/DDDT.S95612. PubMed PMID: 26388688; PubMed Central PMCID: PMC4571929.

13: Balwani M, Burrow TA, Charrow J, Goker-Alpan O, Kaplan P, Kishnani PS, Mistry P, Ruskin J, Weinreb N. Recommendations for the use of eliglustat in the treatment of adults with Gaucher disease type 1 in the United States. Mol Genet Metab. 2016 Feb;117(2):95-103. doi: 10.1016/j.ymgme.2015.09.002. Review. PubMed PMID: 26387627.

14: Scott LJ. Eliglustat: A Review in Gaucher Disease Type 1. Drugs. 2015 Sep;75(14):1669-78. doi: 10.1007/s40265-015-0468-9. Review. PubMed PMID: 26384672.

15: Bennett LL, Turcotte K. Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease. Drug Des Devel Ther. 2015 Aug 18;9:4639-47. doi: 10.2147/DDDT.S77760. Review. Erratum in: Drug Des Devel Ther. 2015;9:5213. PubMed PMID: 26345314; PubMed Central PMCID: PMC4554398.

16: Dagher R, Watzinger M, Chevalier G, Thirion-Delalande C, Gervais F, Forster R. Carcinogenicity testing of eliglustat in mice and rats. Regul Toxicol Pharmacol. 2015 Oct;73(1):401-12. doi: 10.1016/j.yrtph.2015.07.024. PubMed PMID: 26232705.

17: Grzegorek K. [New oral therapy option]. MMW Fortschr Med. 2015 Jul 23;157(13):77. doi: 10.1007/s15006-015-3362-1. German. PubMed PMID: 26206047.

18: Eliglustat (Cerdelga)--An Oral Drug for Gaucher Disease. Med Lett Drugs Ther. 2015 Jul 6;57(1472):e100-1. Review. PubMed PMID: 26147895.

19: Hughes DA, Pastores GM. Eliglustat for Gaucher's disease: trippingly on the tongue. Lancet. 2015 Jun 13;385(9985):2328-30. doi: 10.1016/S0140-6736(15)60206-9. PubMed PMID: 25819692.

20: Cox TM, Drelichman G, Cravo R, Balwani M, Burrow TA, Martins AM, Lukina E, Rosenbloom B, Ross L, Angell J, Puga AC. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomised, open-label, non-inferiority trial. Lancet. 2015 Jun 13;385(9985):2355-62. doi: 10.1016/S0140-6736(14)61841-9. Erratum in: Lancet. 2015 Jun 13;385(9985):2354. PubMed PMID: 25819691.



Additional Information

Related CAS#
928659-70-5 ( Eliglustat hemitartrate );
491833-29-5 ( Eliglustat free base).